PL2606032T3 - Kompozycja i sposoby terapii glejakaep - Google Patents

Kompozycja i sposoby terapii glejakaep

Info

Publication number
PL2606032T3
PL2606032T3 PL11749677T PL11749677T PL2606032T3 PL 2606032 T3 PL2606032 T3 PL 2606032T3 PL 11749677 T PL11749677 T PL 11749677T PL 11749677 T PL11749677 T PL 11749677T PL 2606032 T3 PL2606032 T3 PL 2606032T3
Authority
PL
Poland
Prior art keywords
composition
methods
treating glioblastomas
glioblastomas
treating
Prior art date
Application number
PL11749677T
Other languages
English (en)
Inventor
Nephi Stella
Toni Kline
Original Assignee
Univ Washington Through Its Center For Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington Through Its Center For Commercialization filed Critical Univ Washington Through Its Center For Commercialization
Publication of PL2606032T3 publication Critical patent/PL2606032T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08Nitrogen atoms
    • C07D219/10Nitrogen atoms attached in position 9
    • C07D219/12Amino-alkylamino radicals attached in position 9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL11749677T 2010-08-20 2011-08-22 Kompozycja i sposoby terapii glejakaep PL2606032T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37570410P 2010-08-20 2010-08-20
EP11749677.8A EP2606032B1 (en) 2010-08-20 2011-08-22 Composition and methods for treating glioblastomas
PCT/US2011/048594 WO2012024670A2 (en) 2010-08-20 2011-08-22 Composition and methods for treating glioblastoma

Publications (1)

Publication Number Publication Date
PL2606032T3 true PL2606032T3 (pl) 2015-07-31

Family

ID=44533208

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11749677T PL2606032T3 (pl) 2010-08-20 2011-08-22 Kompozycja i sposoby terapii glejakaep

Country Status (5)

Country Link
US (1) US9034895B2 (pl)
EP (1) EP2606032B1 (pl)
ES (1) ES2530629T3 (pl)
PL (1) PL2606032T3 (pl)
WO (1) WO2012024670A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2638057B1 (es) * 2017-03-02 2018-10-01 Universidad Del País Vasco / Euskal Herriko Unibertsitatea Tratamiento de la demencia con agonistas cannabinoides
WO2020132384A1 (en) 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2
KR20240072339A (ko) * 2022-11-14 2024-05-24 주식회사 힐리노엘에스 교모세포종의 예방, 개선 또는 치료용 화합물을 유효성분으로 포함하는 조성물
CN118812442B (zh) * 2024-06-19 2025-10-03 四川省医学科学院·四川省人民医院 能提升血脑屏障通透性的化合物、其制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
AU2002302248B2 (en) * 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
US20050009903A1 (en) 2003-06-10 2005-01-13 Martin Billy R. CB2-selective cannabinoid analogues

Also Published As

Publication number Publication date
WO2012024670A2 (en) 2012-02-23
EP2606032A2 (en) 2013-06-26
EP2606032B1 (en) 2015-01-07
US9034895B2 (en) 2015-05-19
ES2530629T3 (es) 2015-03-04
US20130197026A1 (en) 2013-08-01
WO2012024670A3 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
IL253870A0 (en) Certain amino-pyrimidines, their assemblies, and methods of using them
SG2014010706A (en) Method and composition
GB201016001D0 (en) Composition and method
ZA201302625B (en) Methods and compositions for treating hemophilia b
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
ZA201303423B (en) Compositions and methods for treating myelofibrosis
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
ZA201208578B (en) Composition,method and use
IL222465A0 (en) Certain amino-pyridazines, compositions thereof, and methods for their use
SG10201500124VA (en) Methods and Compositions for Treating Cancer
GB201122195D0 (en) Composition and method
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
IL225483A0 (en) The compositions and methods for the treatment of neoplasia
IL232648A0 (en) Preparations and methods for treating glioma
GB201003531D0 (en) Composition and method
GB201106433D0 (en) Composition and method
GB201008364D0 (en) Composition and method
EP2566478A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPERTENSION
GB201008843D0 (en) Method and composition
PL2606032T3 (pl) Kompozycja i sposoby terapii glejakaep
GB2500357B (en) Combination and composition for treating obesity
EP2632432A4 (en) COMPOSITION AND METHOD FOR TREATING LESIONS
ZA201308683B (en) Methods and compositions suitable for preventing and treating hyperleptinemia
GB201001243D0 (en) Composition and method
GB201002240D0 (en) Composition and method